Epic Sciences will donate its No Cell Left Behind platform to the clinical trial, which will enroll about 1,000 patients over three years.
The funding will support the British Columbia Cancer Agency's effort to use genome sequencing to develop personalized treatment strategies for cancer patients.
Among 100 adults and six children recruited between June 2012 and August 2014, most were successfully sequenced and a majority of those had actionable results.
Researchers leading the POG trial are hoping this year to sequence the whole genomes of 300 cancer patients in an effort to find the best treatment options for them.
The goal is to analyze a variety of genomic techniques, including sequencing, to develop a test that will determine whether AML patients should receive chemotherapy or stem cell transplantation.
The Genome British Columbia program will kick off with funding totaling around $9 million for three personalized medicine studies.
NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.
Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.
A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.
In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.